Detection of microrna-21 expression as a potential screening biomarker for colorectal cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 18, 2014, Pages 7583-7588

  Jiang, Jian Xin ^a   Zhang, Na ^b   Liu, Zhong Min ^a   Wang, Yan Ying ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HARBIN UNIVERSITY OF COMMERCE   (China)

Author keywords

Colorectal cancer; Diagnosis; Meta analysis; MicroRNA 21

Indexed keywords

MICRORNA; MIRN21 MICRORNA, HUMAN; TUMOR MARKER;

AREA UNDER THE CURVE; CASE CONTROL STUDY; COLON; COLORECTAL NEOPLASMS; GENETICS; HUMAN; META ANALYSIS; METABOLISM; PROGNOSIS; RECTUM;

AREA UNDER CURVE; CASE-CONTROL STUDIES; COLON; COLORECTAL NEOPLASMS; HUMANS; MICRORNAS; PROGNOSIS; RECTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 84908024127     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.18.7583     Document Type: Article

References (41)

1. Ahlquist DA, Sargent DJ, Loprinzi CL, et al (2008). Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med, 149, 441-50.
2. Asangani IA, Rasheed SA, Nikolova DA, et al (2008). MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene, 27, 2128-36.
3. Chan SH, Wu CW, Li AF, et al (2008). miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res, 28, 907-11.
4. Chang KH, Miller N, Kheirelseid EA, et al (2011). MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur J Surg Oncol, 37, 597-603.
5. Deeks JJ, Macaskill P and Irwig L (2005). The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol, 58, 882-93.
6. Dinnes J, Deeks J, Kirby J, et al (2005). A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess, 9, 1-113.
7. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, et al (2009). MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer, 101, 707-14.
8. Fakih MG and Padmanabhan A (2006). CEA monitoring in colorectal cancer. What you should know. Oncology, 20, 579-87.
9. Glas AS, Lijmer JG, Prins MH, et al (2003). The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol, 56, 1129-35.
10. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
11. Huang Q, Liu L, Liu CH, et al (2013). MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis. Asian Pac J Cancer Prev, 14, 829-34.
12. Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.
13. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al (2004). Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med, 351, 2704-14.
14. Janakiram NB, Rao CV (2008). Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin, 29, 1-20.
15. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
16. Kanaan Z, Rai SN, Eichenberger MR, et al (2012b). Plasma MiR-21: A potential diagnostic marker of colorectal cancer. Ann Surg, 256, 544-51.
17. Koga Y, Yasunaga M, Takahashi A, et al (2010a). MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res, 3, 1435-42.
18. Koga Y, Yasunaga M, Takahashi A, et al (2010b). MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res, 3, 1435-42.
19. Kuriyama S, Hamaya Y, Yamada T, et al (2012). Fecal microrna assays as a marker for colorectal cancer screening. Gastroenterology, 142, 770.
20. Lawrie CH, Gal S, Dunlop HM, et al (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 141, 672-5.
21. Li Y, Li W, Ouyang Q, et al (2011). Detection of lung cancer with blood microRNA-21 expression levels in Chinese population. Oncol Lett, 2, 991-4.
22. Liu GH, Zhou ZG, Chen R, et al (2013). Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol, 34, 2175-81.
23. Luo X, Stock C, Burwinkel B, et al (2013). Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS ONE, 8, 62880.
24. Meng F, Henson R, Wehbe-Janek H, et al (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-58.
25. Monzo M, Navarro A, Bandres E, et al (2008). Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res, 18, 823-33.
26. Nagel R, le Sage C, Diosdado B, et al (2008). Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res, 68, 5795-802.
27. Ng EK, Chong WW, Jin H, et al (2009). Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut, 58, 1375-81.
28. O'Connell JB, Maggard MA and Ko CY (2004). Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst, 96, 1420-5.
29. Pu XX, Huang GL, Guo HQ, et al (2010). Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol, 25, 1674-80.
30. Schetter AJ, Leung SY, Sohn JJ, et al (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425-36.
31. Shibuya H, Iinuma H, Shimada R, et al (2010). Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology, 79, 313-20.
32. Slaby O, Svoboda M, Fabian P, et al (2007). Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology, 72, 397-402.
33. Toiyama Y, Takahashi M, Hur K, et al (2013). Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst, 105, 849-59.
34. Wang Y, Gao X, Wei F, et al (2014). Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene, 533, 389-97.
35. Whiting PF, Rutjes AW, Westwood ME, et al (2011). QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 155, 529-36.
36. Wu CW, Ng SSM, Dong YJ, et al (2012b). Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut, 61, 739-45.
37. Xu YZ, Xi QH, Ge WL, et al (2013). Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 1057-60.
38. Yamamichi N, Shimomura R, Inada K, et al (2009). Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res, 15, 4009-16.
39. Zanutto S, Pizzamiglio S, Ghilotti M, et al (2014). Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. Br J Cancer, 110, 1001-7.
40. Zeng Z, Wang J, Zhao L, et al (2013). Potential role of microRNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One, 8, 73278.
41. Zhu S, Si ML, Wu H, et al (2007). MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem, 282, 14328-36.